Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol. 1986

L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano

The interfering effect of sulphinpyrazone, a uricosuric agent which reduces the activity of cyclo-oxygenase, with the antihypertensive activity of oxprenolol, a non-cardioselective beta-blocker with sympathomimetic activity, has been evaluated. Ten patients with primary arterial hypertension of mild to moderate degree entered a randomized double-blind cross-over study versus placebo. They were given oxprenolol + placebo or oxprenolol + sulphinpyrazone for 15 days, and then the treatments were crossed-over for a further 15 days. Oxprenolol significantly reduced blood pressure (161 +/- 3/101 +/- 1 vs 149 +/- 4/96 +/- 2 mmHg) and heart rate (72 +/- 3 vs 66 +/- 3 beats/min). During administration of the combination with sulphinpyrazone the blood pressure increased to its pretreatment level (156 +/- 5/101 +/- 2 mmHg). The effect of oxprenolol on heart rate was not influenced by the combined treatment (67 +/- 6 beats/min). The results may be explained by 1) sulphinpyrazone-induced inhibition of prostaglandin synthesis, which could interfere with the antihypertensive activity of oxprenolol, or 2) sulphinpyrazone-induced acceleration of the metabolism of oxprenolol.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010096 Oxprenolol A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. Coretal,Koretal,Oxprenolol Hydrochloride,Slow Trasicor,Tevacor,Trasicor,Hydrochloride, Oxprenolol,Trasicor, Slow
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug

Related Publications

L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
August 1976, Clinical pharmacology and therapeutics,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
June 1980, Clinical pharmacology and therapeutics,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
January 2001, Journal of inorganic biochemistry,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
March 1976, Clinical pharmacology and therapeutics,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
October 1975, British journal of pharmacology,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
January 1976, Current therapeutic research, clinical and experimental,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
January 1971, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
January 1984, Clinical therapeutics,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
January 1982, Pharmatherapeutica,
L A Ferrara, and M Mancini, and T Marotta, and F Pasanisi, and M L Fasano
April 1987, Archives des maladies du coeur et des vaisseaux,
Copied contents to your clipboard!